NEW
YORK
|
16-0345235
|
(State
or other jurisdiction of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
ONE
BAUSCH & LOMB PLACE, ROCHESTER, NEW YORK
|
14604-2701
|
(Address
of principal executive offices)
|
(Zip
Code)
|
(Unaudited)
Second
Quarter Ended
|
(Unaudited)
Six
Months Ended
|
|||||||||||||||
Dollar
Amounts in Millions - Except Per Share Data
|
June
30,
2007
|
July
1,
2006
|
June
30,
2007
|
July
1,
2006
|
||||||||||||
Net
Sales
|
$ |
649.5
|
$ |
571.5
|
$ |
1,228.4
|
$ |
1,117.5
|
||||||||
Costs
and Expenses
|
||||||||||||||||
Cost
of products
sold
|
273.4
|
249.5
|
521.3
|
488.6
|
||||||||||||
Selling,
administrative and
general
|
280.3
|
256.2
|
511.0
|
486.9
|
||||||||||||
Research
and
development
|
55.0
|
50.0
|
105.2
|
93.5
|
||||||||||||
608.7
|
555.7
|
1,137.5
|
1,069.0
|
|||||||||||||
Operating
Income
|
40.8
|
15.8
|
90.9
|
48.5
|
||||||||||||
Other
(Income) Expense
|
||||||||||||||||
Interest
and investment
income
|
(9.8 | ) | (6.8 | ) | (18.7 | ) | (15.5 | ) | ||||||||
Interest
expense
|
15.4
|
18.1
|
30.8
|
34.3
|
||||||||||||
Foreign
currency,
net
|
0.6
|
2.4
|
2.2
|
3.2
|
||||||||||||
6.2
|
13.7
|
14.3
|
22.0
|
|||||||||||||
Income
before Income Taxes and Minority Interest
|
34.6
|
2.1
|
76.6
|
26.5
|
||||||||||||
Provision
for income
taxes
|
18.1
|
18.2
|
41.2
|
30.2
|
||||||||||||
Minority
interest in
subsidiaries
|
1.5
|
(1.0 | ) |
1.9
|
(0.4 | ) | ||||||||||
Net
Income (Loss)
|
$ |
15.0
|
$ | (15.1 | ) | $ |
33.5
|
$ | (3.3 | ) | ||||||
Basic
Earnings (Loss) Per Share
|
$ |
0.28
|
$ | (0.28 | ) | $ |
0.62
|
$ | (0.06 | ) | ||||||
Average
Shares Outstanding - Basic (000s)
|
54,134
|
53,789
|
54,061
|
53,722
|
||||||||||||
Diluted
Earnings (Loss) Per Share
|
$ |
0.27
|
$ | (0.28 | ) | $ |
0.60
|
$ | (0.06 | ) | ||||||
Average
Shares Outstanding - Diluted (000s)
|
55,812
|
53,789
|
55,459
|
53,722
|
Dollar
Amounts in Millions - Except Per Share Data
|
(Unaudited)
June
30,
2007
|
December
30,
2006
|
||||||
Assets
|
||||||||
Cash
and cash
equivalents
|
$ |
547.7
|
$ |
499.9
|
||||
Trade
receivables, less
allowances of $17.7 and $17.0, respectively
|
488.6
|
444.7
|
||||||
Inventories,
net
|
251.2
|
237.4
|
||||||
Other
current
assets
|
164.2
|
160.0
|
||||||
Deferred
income
taxes
|
57.4
|
60.1
|
||||||
Total
Current Assets
|
1,509.1
|
1,402.1
|
||||||
Property,
Plant and Equipment, net
|
619.3
|
633.2
|
||||||
Goodwill
|
857.1
|
846.2
|
||||||
Other
Intangibles, net
|
266.3
|
278.2
|
||||||
Other
Long-Term Assets
|
113.6
|
102.4
|
||||||
Deferred
Income Taxes
|
15.8
|
16.7
|
||||||
Total
Assets
|
$ |
3,381.2
|
$ |
3,278.8
|
||||
Liabilities
and Shareholders' Equity
|
||||||||
Notes
payable
|
$ |
0.2
|
$ |
2.7
|
||||
Current
portion of long-term
debt
|
133.9
|
134.4
|
||||||
Accounts
payable
|
82.8
|
83.2
|
||||||
Accrued
compensation
|
126.4
|
118.5
|
||||||
Accrued
liabilities
|
392.5
|
386.5
|
||||||
Federal,
state and foreign
income taxes payable
|
66.6
|
145.7
|
||||||
Deferred
income
taxes
|
0.5
|
0.8
|
||||||
Total
Current Liabilities
|
802.9
|
871.8
|
||||||
Long-Term
Debt, less current portion
|
696.5
|
698.3
|
||||||
Pension
and Other Benefit Liabilities
|
173.0
|
176.0
|
||||||
Other
Long-Term Liabilities
|
9.5
|
10.5
|
||||||
Income
Tax Liabilities
|
88.4
|
-
|
||||||
Deferred
Income Taxes
|
125.0
|
110.2
|
||||||
Total
Liabilities
|
1,895.3
|
1,866.8
|
||||||
Minority
Interest
|
17.7
|
17.2
|
||||||
Commitments
and Contingencies (Note 8)
|
||||||||
Common
Stock, par value $0.40 per share, 200 million shares authorized,
60,486,775 shares issued (60,457,108 shares in 2006)
|
24.1
|
24.1
|
||||||
Class
B Stock, par value $0.08 per share, 15 million shares authorized,
179,778
shares issued (187,694 shares in 2006)
|
-
|
-
|
||||||
Capital
in Excess of Par Value
|
109.5
|
117.9
|
||||||
Common
and Class B Stock in Treasury, at cost, 5,675,281 shares (6,715,647
shares
in 2006)
|
(301.7 | ) | (354.7 | ) | ||||
Retained
Earnings
|
1,459.5
|
1,458.3
|
||||||
Accumulated
Other Comprehensive Income
|
176.8
|
149.2
|
||||||
Total
Shareholders' Equity
|
1,468.2
|
1,394.8
|
||||||
Total
Liabilities and Shareholders' Equity
|
$ |
3,381.2
|
$ |
3,278.8
|
(Unaudited)
Six
Months Ended
|
||||||||
Dollar
Amounts in Millions
|
June
30,
2007
|
July
1,
2006
|
||||||
Cash
Flows from Operating Activities
|
||||||||
Net
Income (Loss)
|
$ |
33.5
|
$ | (3.3 | ) | |||
Adjustments
to Reconcile Net Income (Loss) to Net Cash Provided by Operating
Activities
|
||||||||
Depreciation
|
51.5
|
51.1
|
||||||
Amortization
|
15.9
|
15.2
|
||||||
Deferred
income
taxes
|
18.2
|
0.6
|
||||||
Stock-based
compensation
expense
|
4.3
|
2.0
|
||||||
Tax
benefits associated with
exercise of stock options
|
(0.7 | ) |
-
|
|||||
Gain
from sale of investments
available-for-sale
|
(2.8 | ) |
-
|
|||||
Loss
on retirement of fixed
assets
|
0.2
|
0.8
|
||||||
Changes
in Assets and Liabilities
|
||||||||
Trade
receivables
|
(39.0 | ) |
53.4
|
|||||
Inventories
|
(11.3 | ) | (39.7 | ) | ||||
Other
current
assets
|
(3.3 | ) | (16.0 | ) | ||||
Other
long-term assets, including
equipment on operating lease
|
3.5
|
2.2
|
||||||
Accounts
payable and accrued
liabilities
|
(8.9 | ) | (27.8 | ) | ||||
Income
taxes
payable
|
(79.0 | ) | (16.3 | ) | ||||
Other
long-term
liabilities
|
88.6
|
3.4
|
||||||
Net
Cash Provided by Operating Activities
|
70.7
|
25.6
|
||||||
Cash
Flows from Investing Activities
|
||||||||
Capital
expenditures
|
(29.6 | ) | (66.5 | ) | ||||
Net
cash paid for acquisition of
businesses and other intangibles
|
(3.1 | ) | (34.3 | ) | ||||
Cash
paid for investment in equity
securities
|
(15.0 | ) |
-
|
|||||
Cash
received from sale of
investments available-for-sale
|
2.8
|
-
|
||||||
Other
|
(3.2 | ) | (0.8 | ) | ||||
Net
Cash Used in Investing Activities
|
(48.1 | ) | (101.6 | ) | ||||
Cash
Flows from Financing Activities
|
||||||||
Repurchase
of Common and Class B
shares
|
(4.4 | ) | (1.8 | ) | ||||
Exercise
of stock
options
|
43.2
|
0.1
|
||||||
Tax
benefits associated with
exercise of stock options
|
0.7
|
-
|
||||||
Net
repayments of notes
payable
|
(0.1 | ) |
0.1
|
|||||
Repayment
of long-term
debt
|
(0.5 | ) | (143.5 | ) | ||||
Net
distributions to minority
interests
|
(1.2 | ) |
-
|
|||||
Payment
of
dividends
|
(14.4 | ) | (14.4 | ) | ||||
Net
Cash Provided by (Used in) Financing Activities
|
23.3
|
(159.5 | ) | |||||
Effect
of exchange rate changes on cash and cash equivalents
|
1.9
|
3.9
|
||||||
Net
Change in Cash and Cash Equivalents
|
47.8
|
(231.6 | ) | |||||
Cash
and Cash Equivalents - Beginning of Period
|
499.9
|
720.6
|
||||||
Cash
and Cash Equivalents - End of Period
|
$ |
547.7
|
$ |
489.0
|
||||
Supplemental
Cash Flow Disclosures
|
||||||||
Cash
paid for interest (net of
portion capitalized)
|
$ |
24.9
|
$ |
28.9
|
||||
Net
cash payments for income
taxes
|
$ |
33.1
|
$ |
54.0
|
||||
Supplemental
Schedule of Non-Cash Financing Activities
|
||||||||
Dividends
declared but not
paid
|
$ |
7.1
|
$ |
7.0
|
Second
Quarter Ended
|
Six
Months Ended
|
|||||||||||||||
June
30,
2007
|
July
1,
2006
|
June
30,
2007
|
July
1,
2006
|
|||||||||||||
Foreign
currency translation adjustments
|
$ |
13.8
|
$ |
47.9
|
$ |
25.7
|
$ |
53.9
|
||||||||
Employee
benefit plan activity
|
1.6
|
-
|
3.1
|
-
|
||||||||||||
Realized
losses from hedging activity
|
0.7
|
0.7
|
1.4
|
0.2
|
||||||||||||
Realized
gains from sales of available-for-sale securities
|
(0.5 | ) |
-
|
(2.8 | ) |
-
|
||||||||||
Market
value adjustments for available-for-sale securities
|
(0.3 | ) |
-
|
0.2
|
2.1
|
|||||||||||
Other
comprehensive income 1
|
15.3
|
48.6
|
27.6
|
56.2
|
||||||||||||
Net
income (loss)
|
15.0
|
(15.1 | ) |
33.5
|
(3.3 | ) | ||||||||||
Total
comprehensive income
|
$ |
30.3
|
$ |
33.5
|
$ |
61.1
|
$ |
52.9
|
1
|
In
Q2 2007 the Company designated as a cash flow hedge a foreign exchange
forward contract in the notional amount of $9.7 at June 30, 2007
to hedge
foreign currency exposure associated with an intercompany loan
denominated
in Japanese yen. The hedge termination date is December 2007
concurrent with the maturity of the intercompany loan. The
unrealized gain on the hedge for the quarter and year-to-date periods
ended June 30, 2007 was less than
$0.1.
|
Second
Quarter Ended
|
Six
Months Ended
|
|||||||||||||||
Dollar
Amounts in Millions - Except Per Share Data, Number of Shares in
Thousands
|
June
30,
2007
|
July
1,
2006
|
June
30,
2007
|
July
1,
2006
|
||||||||||||
Net
Income (Loss)
|
$ |
15.0
|
$ | (15.1 | ) | $ |
33.5
|
$ | (3.3 | ) | ||||||
Weighted
Average Basic Shares Outstanding
|
54,134
|
53,789
|
54,061
|
53,722
|
||||||||||||
Effect
of Dilutive
Shares
|
1,553
|
993
|
1,331
|
1,537
|
||||||||||||
Effect
of Convertible Senior
Notes Shares
|
67
|
67
|
67
|
67
|
||||||||||||
Effect
of 2004 Senior
Convertible Securities Shares
|
58
|
-
|
-
|
-
|
||||||||||||
Weighted
Average Diluted Shares Outstanding 1
|
55,812
|
54,849
|
55,459
|
55,326
|
||||||||||||
Basic
Earnings (Loss) Per Share
|
$ |
0.28
|
$ | (0.28 | ) | $ |
0.62
|
$ | (0.06 | ) | ||||||
Diluted
Earnings (Loss) Per Share
|
$ |
0.27
|
$ | (0.28 | ) | $ |
0.60
|
$ | (0.06 | ) |
1
|
As
a result of the net loss presented for the second quarter and six
months
ended July 1, 2006, the Company calculates diluted earnings per
share
using weighted average basic shares outstanding for each period,
as
utilizing diluted shares would be anti-dilutive to loss per
share.
|
Second
Quarter Ended
|
Six
Months Ended
|
|||||||||||||||
June
30,
2007
|
July
1,
2006
|
June
30,
2007
|
July
1,
2006
|
|||||||||||||
Income
before income taxes and minority interest
|
$ |
34.6
|
$ |
2.1
|
$ |
76.6
|
$ |
26.5
|
||||||||
Provision
for income taxes
|
18.1
|
18.2
|
41.2
|
30.2
|
||||||||||||
Effective
tax rate
|
52.3 | % | 866.7 | % | 53.8 | % | 114.0 | % |
Open
Tax Years
|
||
Jurisdiction
|
Examination
in Progress
|
Examination
Not Yet Initiated
|
United
States 1
|
1996-2004
|
2005-2006
|
Brazil
|
N/A
|
2002-2006
|
Germany
1
|
1995-2004
|
2005-2006
|
Spain
|
2003-2004
|
2002,
2005-2006
|
France
|
2002-2003
|
2004-2006
|
China
1
|
N/A
|
1997-2006
|
Ireland
|
N/A
|
2002-2006
|
Scotland
|
N/A
|
2004-2006
|
United
Kingdom
|
2004
|
2005-2006
|
Netherlands
|
2002
|
2003-2006
|
Japan
1
|
N/A
|
2001-2006
|
Belgium
|
2004-2005
|
2006
|
Korea
1
|
N/A
|
2002-2006
|
Second
Quarter Ended
|
||||||||||||||||
June
30, 2007
|
July
1, 2006
|
|||||||||||||||
Net
Sales
|
Operating
Income
|
Net
Sales
|
Operating
Income
|
|||||||||||||
Americas
|
$ |
272.8
|
$ |
82.7
|
$ |
250.2
|
$ |
64.7
|
||||||||
Europe
|
252.2
|
74.7
|
217.0
|
57.9
|
||||||||||||
Asia
|
124.5
|
23.2
|
104.3
|
8.2
|
||||||||||||
Research
& Development
|
-
|
(62.6 | ) |
-
|
(56.3 | ) | ||||||||||
Global
Operations & Engineering
|
-
|
(40.9 | ) |
-
|
(37.4 | ) | ||||||||||
649.5
|
77.1
|
571.5
|
37.1
|
|||||||||||||
Corporate
administration
|
-
|
(36.3 | ) |
-
|
(21.3 | ) | ||||||||||
$ |
649.5
|
$ |
40.8
|
$ |
571.5
|
$ |
15.8
|
Six
Months Ended
|
||||||||||||||||
June
30, 2007
|
July
1, 2006
|
|||||||||||||||
Net
Sales
|
Operating
Income
|
Net
Sales
|
Operating
Income
|
|||||||||||||
Americas
|
$ |
514.9
|
$ |
176.1
|
$ |
497.7
|
$ |
145.6
|
||||||||
Europe
|
482.3
|
147.1
|
403.4
|
91.3
|
||||||||||||
Asia
|
231.2
|
40.5
|
216.4
|
28.3
|
||||||||||||
Research
& Development
|
-
|
(121.0 | ) |
-
|
(104.7 | ) | ||||||||||
Global
Operations & Engineering
|
-
|
(80.7 | ) |
-
|
(71.5 | ) | ||||||||||
1,228.4
|
162.0
|
1,117.5
|
89.0
|
|||||||||||||
Corporate
administration
|
-
|
(71.1 | ) |
-
|
(40.5 | ) | ||||||||||
$ |
1,228.4
|
$ |
90.9
|
$ |
1,117.5
|
$ |
48.5
|
Pension
Benefit Plans
|
Postretirement
Benefit Plan
|
|||||||||||||||
Second
Quarter Ended
|
Second
Quarter Ended
|
|||||||||||||||
June
30,
2007
|
July
1,
2006
|
June
30,
2007
|
July
1,
2006
|
|||||||||||||
Service
cost
|
$ |
1.9
|
$ |
2.4
|
$ |
0.3
|
$ |
0.3
|
||||||||
Interest
cost
|
5.4
|
5.1
|
1.5
|
1.4
|
||||||||||||
Expected
return on plan assets
|
(6.5 | ) | (5.7 | ) | (0.9 | ) | (0.8 | ) | ||||||||
Amortization
of prior-service cost
|
0.1
|
0.1
|
(0.1 | ) | (0.1 | ) | ||||||||||
Amortization
of net loss
|
1.3
|
2.0
|
0.3
|
0.5
|
||||||||||||
Special
termination benefits
|
-
|
0.2
|
-
|
-
|
||||||||||||
Net
periodic benefit cost
|
$ |
2.2
|
$ |
4.1
|
$ |
1.1
|
$ |
1.3
|
Pension
Benefit Plans
|
Postretirement
Benefit Plan
|
|||||||||||||||
Six
Months Ended
|
Six
Months Ended
|
|||||||||||||||
June
30,
2007
|
June
1,
2006
|
June
30,
2007
|
July
1,
2006
|
|||||||||||||
Service
cost
|
$ |
3.8
|
$ |
4.6
|
$ |
0.6
|
$ |
0.6
|
||||||||
Interest
cost
|
10.8
|
10.1
|
2.9
|
2.8
|
||||||||||||
Expected
return on plan assets
|
(12.9 | ) | (11.3 | ) | (1.8 | ) | (1.6 | ) | ||||||||
Amortization
of prior-service cost
|
0.1
|
0.1
|
(0.1 | ) | (0.1 | ) | ||||||||||
Amortization
of net loss
|
2.6
|
4.0
|
0.6
|
1.0
|
||||||||||||
Special
termination benefits
|
-
|
0.4
|
-
|
-
|
||||||||||||
Net
periodic benefit cost
|
$ |
4.4
|
$ |
7.9
|
$ |
2.2
|
$ |
2.7
|
Balance
at December 31, 2005 1
|
$ |
5.9
|
||
Accruals
for warranties issued
|
7.9
|
|||
Changes
in accruals related to pre-existing warranties
|
(0.5 | ) | ||
Settlements
made
|
(6.8 | ) | ||
Balance
at December 30, 2006 1
|
$ |
6.5
|
||
Accruals
for warranties issued
|
2.4
|
|||
Changes
in accruals related to pre-existing warranties
|
(0.2 | ) | ||
Settlements
made
|
(2.5 | ) | ||
Balance
at June 30, 2007
|
$ |
6.2
|
1
|
Warranty
reserve changes during 2006, as well as the 2005 and 2006 year
end
balances, do not include amounts in connection with the
MoistureLoc recall.
|
Balance
at December 31, 2005
|
$ |
6.9
|
||
Accruals
for service contracts
|
11.7
|
|||
Changes
in accruals related to pre-existing service contracts
|
(0.6 | ) | ||
Revenue
recognized
|
(12.4 | ) | ||
Balance
at December 30, 2006
|
$ |
5.6
|
||
Accruals
for service contracts
|
6.3
|
|||
Changes
in accruals related to pre-existing service contracts
|
(0.5 | ) | ||
Revenue
recognized
|
(6.0 | ) | ||
Balance
at June 30, 2007
|
$ |
5.4
|
June
30,
2007
|
December
30,
2006
|
|||||||
Inventories,
net
|
||||||||
Raw
materials and supplies
|
$ |
65.4
|
$ |
54.3
|
||||
Work
in process
|
21.4
|
18.8
|
||||||
Finished
products
|
164.4
|
164.3
|
||||||
$ |
251.2
|
$ |
237.4
|
June
30,
2007
|
December
30,
2006
|
|||||||
Property,
Plant and Equipment, net
|
||||||||
Land
|
$ |
20.9
|
$ |
20.6
|
||||
Buildings
|
391.8
|
374.1
|
||||||
Machinery
and equipment
|
1,094.6
|
1,089.9
|
||||||
Leasehold
improvements
|
28.0
|
26.6
|
||||||
Equipment
on operating lease
|
19.9
|
18.1
|
||||||
1,555.2
|
1,529.3
|
|||||||
Less
accumulated depreciation
|
(935.9 | ) | (896.1 | ) | ||||
$ |
619.3
|
$ |
633.2
|
Net
Sales
|
Percent
Increase
(Decrease)
Actual
Dollars
|
Percent
Increase
(Decrease)
Constant
Currency
|
Percent
of
Total
Company
Net
Sales
|
|||||||||||||
Quarter
Ended June 30, 2007
|
||||||||||||||||
Non-U.S.
|
$ |
412.3
|
18 | % | 13 | % | 63 | % | ||||||||
U.S.
1
|
237.2
|
7 | % | 7 | % | 37 | % | |||||||||
Total
Company
|
$ |
649.5
|
14 | % | 11 | % | ||||||||||
Quarter
Ended July 1, 2006
|
||||||||||||||||
Non-U.S.
|
$ |
350.1
|
(7 | %) | (7 | %) | 61 | % | ||||||||
U.S.
1
|
221.4
|
(3 | %) | (3 | %) | 39 | % | |||||||||
Total
Company
|
$ |
571.5
|
(6 | %) | (6 | %) | ||||||||||
Six
Months Ended June 30, 2007
|
||||||||||||||||
Non-U.S.
|
$ |
777.4
|
15 | % | 9 | % | 63 | % | ||||||||
U.S.
1
|
451.0
|
2 | % | 2 | % | 37 | % | |||||||||
Total
Company
|
$ |
1,228.4
|
10 | % | 6 | % | ||||||||||
Six
Months Ended July 1, 2006
|
||||||||||||||||
Non-U.S.
2
|
$ |
674.9
|
(6 | %) | (3 | %) | 60 | % | ||||||||
U.S.
1
|
442.6
|
1 | % | 1 | % | 40 | % | |||||||||
Total
Company
|
$ |
1,117.5
|
(4 | %) | (2 | %) |
2
|
2006
year-to-date amounts reflect the impact of the voluntary recall
of
MoistureLoc discussed in Recent Developments above and
in Part I, Item 1. Financial Statements of this Quarterly Report
on Form 10-Q under Note 12 — Market Withdrawal of MoistureLoc Lens
Care Solution. Charges associated with the recall reduced non-U.S.
net sales by $19.1.
|
Net
Sales
|
Percent
Increase
(Decrease)
Actual
Dollars
|
Percent
Increase
(Decrease)
Constant
Currency
|
||||||||||
Quarter
Ended June 30, 2007
|
||||||||||||
Americas
|
$ |
272.8
|
9 | % | 8 | % | ||||||
Europe
|
252.2
|
16 | % | 9 | % | |||||||
Asia
|
124.5
|
19 | % | 19 | % | |||||||
Total
Company
|
$ |
649.5
|
14 | % | 11 | % | ||||||
Quarter
Ended July 1, 2006
|
||||||||||||
Americas
|
$ |
250.2
|
(2 | %) | (3 | %) | ||||||
Europe
|
217.0
|
(4 | %) | (4 | %) | |||||||
Asia
|
104.3
|
(16 | %) | (14 | %) | |||||||
Total
Company
|
$ |
571.5
|
(6 | %) | (6 | %) | ||||||
Six
Months Ended June 30, 2007
|
||||||||||||
Americas
|
$ |
514.9
|
3 | % | 3 | % | ||||||
Europe
|
482.3
|
20 | % | 11 | % | |||||||
Asia
|
231.2
|
7 | % | 6 | % | |||||||
Total
Company
|
$ |
1,228.4
|
10 | % | 6 | % | ||||||
Six
Months Ended July 1, 2006 1
|
||||||||||||
Americas
|
$ |
497.7
|
1 | % | - | % | ||||||
Europe
|
403.4
|
(9 | %) | (5 | %) | |||||||
Asia
|
216.4
|
(4 | %) | - | % | |||||||
Total
Company
|
$ |
1,117.5
|
(4 | %) | (2 | %) |
1
|
2006
amounts reflect the impact of the voluntary recall of MoistureLoc
discussed in Recent Developments above and in Part I, Item 1.
Financial Statements of this Quarterly Report on Form 10-Q under
Note 12 — Market Withdrawal of MoistureLoc Lens Care Solution.
Provisions for sales returns and consumer rebates associated with
the
recall reduced year-to-date Americas region net sales by $0.6,
Europe
region net sales by $18.0 and Asia region net sales by
$0.5.
|
·
|
Second-quarter
Americas segment net sales increased 9 percent from 2006, or 8
percent in
constant currency, with gains in each of our product categories
except for
refractive surgery. On a year-to-date basis, Americas segment net
sales
increased 3 percent from the same period in 2006. Prior-year figures
included approximately $1 in sales return and consumer rebate provisions
associated with the MoistureLoc recall. Sales growth reflected
higher sales of pharmaceuticals, contact lenses and cataract/vitreoretinal
surgery products and lower sales in the lens care and refractive
surgery
categories.
|
·
|
Europe
segment net sales increased 16 percent in the second quarter, and
9
percent in constant currency, with gains in all product categories.
On a
year-to-date basis, Europe segment net sales grew 20 percent, or
11
percent in constant currency. Prior-year results included $18 in
sales
return and consumer rebate provisions associated with the
MoistureLoc recall. Excluding those provisions, Europe segment
sales grew 14 percent, or 6 percent in constant currency, in the
first six
months of 2007. Those trends reflected higher sales of contact
lenses,
pharmaceuticals and surgical products and lower sales of lens care
products.
|
·
|
Second-quarter
Asia segment net sales increased 19 percent from 2006, with
constant-currency gains in all product categories except for refractive
and cataract/vitreoretinal surgery. For the year-to-date period,
sales
increased 7 percent and were up 6 percent on a constant-currency
basis.
The prior-year figures included approximately $1 in sales return
and
consumer rebate provisions associated with the MoistureLoc
recall. Excluding those items, year-to-date Asia segment sales
increased 7
percent, or 5 percent in constant currency, reflecting similar
trends as
the quarter-to-date period.
|
Quarter
Ended June 30, 2007
|
Six
Months Ended June 30, 2007
|
|||||||||||||||
Percent
Increase (Decrease)
|
Percent
Increase
(Decrease)
|
|||||||||||||||
Actual
Dollars
|
Constant
Currency
|
Actual
Dollars
|
Constant
Currency
|
|||||||||||||
Contact
Lens
|
8 | % | 8 | % | 8 | % | 7 | % | ||||||||
Lens
Care 1
|
4 | % | 3 | % | (11 | %) | (11 | %) | ||||||||
Pharmaceuticals
|
17 | % | 17 | % | 13 | % | 13 | % | ||||||||
Cataract/Vitreoretinal
|
7 | % | 6 | % | 4 | % | 3 | % | ||||||||
Refractive
|
- | % | (1 | %) | (2 | %) | (2 | %) | ||||||||
Total
Americas
|
9 | % | 8 | % | 3 | % | 3 | % |
1
|
2006
amounts reflect the impact of the voluntary recall of MoistureLoc
discussed in Recent Developments above and in Part I, Item 1.
Financial Statements of this Quarterly Report on Form 10-Q under
Note 12 — Market Withdrawal of MoistureLoc Lens Care Solution.
Provisions for sales returns and consumer rebates associated with
the
recall reduced year-to-date Americas region net sales by
$0.6.
|
·
|
Contact
lens category growth for both the quarter and
year-to-date periods was due to advances in sales of single vision
spherical (SVS) products, led by the PureVision brand of silicone
hydrogel lenses, combined with overall higher sales of both toric
and
multifocal contact lenses. As expected, sales of our SofLens
brands of disposable, traditional hydrogel contact lenses
declined,
reflecting market shifts to silicone hydrogel
platforms.
|
·
|
Second-quarter
and year-to-date 2007 lens care sales were in line with our expectations.
For the quarter, overall higher sales reflect lower coupon and
rebate
activity (reported as an offset to gross sales), because we issued
refund
coupons and conversion incentives during last year’s MoistureLoc
recall. In addition, our Boston lines of lens care products for
RGP contact lenses rose about 5 percent, reflecting market share
gains and
a price increase in the United States earlier in the year. Sales
of
multipurpose solutions declined as compared to the year ago period,
due to
the lack of MoistureLoc revenues in the current year, combined
with market share losses for our other lines of multipurpose solutions
following the recall. Comparisons were also impacted by customer
restocking orders in May and June of 2006 for non-MoistureLoc
products following the recall. We estimate that as of the
end of the
second quarter of 2007, our unit share of the U.S. market for multipurpose
solutions increased to just over 20 percent, compared to about
18 percent
at the end of 2006. For the year-to-date period, declines in 2007
mainly
reflected the lack of MoistureLoc revenues and market share
losses following the recall.
|
·
|
In
the pharmaceuticals category, Americas region sales of Alrex,
Zylet and Lotemax ophthalmic drops containing
loteprednol etabonate each grew strongly in the second quarter,
benefiting
from increased sales force efforts combined with increased visibility
among eye care practitioners for Lotemax as an adjunct therapy
for treating ocular surface inflammation associated with dry eye.
Our
lines of ocular vitamins posted gains of more than 10 percent,
led by the
PreserVision brand. Also contributing to overall growth were
higher sales of Retisert drug delivery implants and general eye
care products, especially the recently launched Alaway product
for relieving eye itch associated with allergies. Sales trends
also
reflected lower revenues from certain generic non-ophthalmic products
as
compared to the year-ago period. Year-to-date trends were due to
similar
factors.
|
·
|
Higher
sales of cataract/vitreoretinal products in the second quarter
of 2007
were mainly due to gains of about 25 percent for our lines of IOLs,
reflecting continued positive response to our premium-priced
SofPort Advanced Optics and SofPort Advanced Optics with
Violet Shield Technology IOLs. Sales of
phacoemulsification products declined about 5 percent from the
prior year,
as customers anticipate availability of our new Stellaris
platform later in 2007.
|
·
|
Refractive
category performance in the second quarter and year-to-date period
reflects higher revenues from the sale of lasers and equipment
upgrades
and increased service revenue. Revenues from microkeratome blades
and
per-procedure cards declined from the year-ago period, largely
reflecting
the loss of a large U.S. customer contract late in 2006 and, in
the case
of blades, to overall market shifts toward surface ablations and
femtosecond flap creation.
|
Quarter
Ended June 30, 2007
|
Six
Months Ended June 30, 2007
|
|||||||||||||||
Percent
Increase
|
Percent
Increase
|
|||||||||||||||
Actual
Dollars
|
Constant
Currency
|
Actual
Dollars
|
Constant
Currency
|
|||||||||||||
Contact
Lens
|
13 | % | 6 | % | 15 | % | 7 | % | ||||||||
Lens
Care 1
|
11 | % | 4 | % | 45 | % | 37 | % | ||||||||
Pharmaceuticals
|
24 | % | 16 | % | 22 | % | 13 | % | ||||||||
Cataract/Vitreoretinal
|
13 | % | 7 | % | 11 | % | 3 | % | ||||||||
Refractive
|
8 | % | 2 | % | 15 | % | 7 | % | ||||||||
Total
Europe
|
16 | % | 9 | % | 20 | % | 11 | % |
1
|
2006
amounts reflect the impact of the voluntary recall of MoistureLoc
discussed in Recent Developments above and in Part I, Item 1.
Financial Statements of this Quarterly Report on Form 10-Q under
Note 12 — Market Withdrawal of MoistureLoc Lens Care Solution.
Provisions for sales returns and consumer rebates associated with
the
recall reduced year-to-date Europe region net sales by
$18.0.
|
·
|
Contact
lens sales increases are primarily attributable to higher sales
of
PureVision silicone hydrogel products. These gains outpaced
declines for traditional hydrogel products (as the market transitions
to
silicone hydrogel materials) and certain other contact lenses we
are
discontinuing. Sales of daily disposable contact lenses declined
nearly 10
percent from the prior year quarter. We completed the launch of
our new
SofLens Daily Disposable lenses in the region in the second
quarter, and continue to believe the introduction of a new packaging
configuration and focused promotional activities should help to
reverse
these sales trends in the second half of
2007.
|
·
|
Lens
care sales growth in the second quarter was mainly due to higher
sales of
ReNu branded multipurpose solutions. Reported year-to-date
lens
care sales growth reflects the impact of sales returns and other
sales
adjustments associated with the MoistureLoc recall that were
recorded in the first quarter of 2006. Excluding those items, European
lens care sales were down 1 percent on a reported basis and 8 percent
in
constant currency, due to lost MoistureLoc sales and market share
declines for our lines of soft contact lens solutions following
the
recall.
|
·
|
Constant-currency
European pharmaceuticals sales growth in the second quarter of
2007 was
mainly attributable to higher sales across our ophthalmic product
lines,
especially related to products for treating dry eye and inflammation,
combined with higher sales of ocular vitamins. For the year-to-date
period, higher sales of allergy products were also a contributing
factor.
|
·
|
Constant-currency
sales gains in the cataract/vitreoretinal category for both the
quarter
and year-to-date periods were mainly due to our lines of IOLs and
disposable products. IOL sales growth of about 10 percent in the
quarter
and first six months of the year reflected continued market acceptance
of
our Akreos acrylic IOLs, including the micro incision model which
is in its first full year of
distribution.
|
·
|
Second-quarter
2007 refractive surgery sales growth in Europe was mainly due to
increased
sales of per-procedure cards and service revenues. For the year-to-date
period, growth reflected higher sales of per-procedure cards, capital
equipment and upgrades and microkeratome
blades.
|
Quarter
Ended June 30, 2007
|
Six
Months Ended June 30, 2007
|
|||||||||||||||
Percent
Increase (Decrease)
|
Percent
Increase (Decrease)
|
|||||||||||||||
Actual
Dollars
|
Constant
Currency
|
Actual
Dollars
|
Constant
Currency
|
|||||||||||||
Contact
Lens
|
8 | % | 10 | % | 2 | % | 2 | % | ||||||||
Lens
Care 1
|
36 | % | 36 | % | 29 | % | 29 | % | ||||||||
Pharmaceuticals
|
82 | % | 75 | % | 13 | % | 8 | % | ||||||||
Cataract/Vitreoretinal
|
- | % | (5 | %) | - | % | (4 | %) | ||||||||
Refractive
|
(23 | %) | (26 | %) | (21 | %) | (24 | %) | ||||||||
Total
Asia
|
19 | % | 19 | % | 7 | % | 6 | % |
1
|
2006
amounts reflect the impact of the voluntary recall of MoistureLoc
discussed in Recent Developments above and in Part I, Item 1.
Financial Statements of this Quarterly Report on Form 10-Q under
Note 12 — Market Withdrawal of MoistureLoc Lens Care Solution.
Provisions for sales returns and consumer rebates associated with
the
recall reduced year-to-date Asia region net sales by
$0.5.
|
·
|
Second-quarter
2007 contact lens sales growth in Asia was largely due to advances
in
China, where sales more than doubled from depressed levels of a
year ago
caused by collateral impacts from the MoistureLoc recall. Gains
were also noted in Japan,
where revenues increased close to 10 percent in constant currency.
Late in
the quarter we began shipping PureVision
SVS and PureVision
Toric silicone hydrogel contact
lenses to customers in Japan following regulatory approval of these
products earlier in the year. On a year-to-date basis, Asia region
contact
lens sales in markets outside of Japan grew more than five
percent. Japanese contact lens sales declined over this period,
reflecting the impact of a change in accounting methodology for
sales to
two large Japanese distributors. As previously discussed in our
Form 10-Q
for the first quarter of 2007, in the first and second quarters of
2006, shipments to these distributors were accounted for as consignment
sales, and we recorded revenue as the distributor sold product
to their
customers. Due to reductions in the amount of inventory carried
by these
distributors throughout 2006, and in accordance with our revenue
recognition policy, starting in the fourth quarter of 2006 we began
recording revenues upon shipment to the distributors. Sell-through
of
product by the distributors in the first six months of 2006 exceeded
shipments to them in the first six months of
2007.
|
·
|
Lens
care sales growth continued to gain momentum in the second quarter,
as our
business continues to recover following the MoistureLoc recall.
While higher sales were reported in every market in the region,
gains were
especially strong in China, where we estimate our market share
increased
to 30 percent by the end of the second quarter – about 10 share points
lower than our share prior to the recall, but up from levels of
the prior
year and quarter. Current-year sales also benefited from our return
to the
market in both Hong Kong and Malaysia, where we had withdrawn our
ReNu branded products in
2006.
|
·
|
Second-quarter
2007 pharmaceuticals sales increases in Asia reflect a comparison
to prior
year sales which were depressed due to the collateral effects of
the
MoistureLoc recall and the timing of finalizing annual contracts
with distributors and retail accounts in China. For the year-to-date
period, sales growth was due to higher sales of dry eye and allergy
products in China, combined with gains for our lines of ocular
vitamins in
other markets in the region. In the second half of 2006 we adopted
a
distributor model for certain non-ophthalmic products formerly
sold
directly through our Chinese sales force. As a result, sales declined
for
those lines of products in both the quarter and year-to-date
periods.
|
·
|
In
the cataract/vitreoretinal category, sales of IOLs increased more
than 10
percent on a constant-currency basis in the second quarter as we
introduced the Akreos brand of acrylic IOLs in additional
markets. Overall sales declines in the category reflect lower sales
of
phacoemulsification products due to fewer equipment placements
as
customers await the availability of our new Stellaris platform
later in 2007. Year-to-date performance in this product category
was due
to similar trends.
|
·
|
Refractive
category sales declined in Asia for both the quarter and year-to-date
periods. The impact of lower equipment sales was partially mitigated
by
higher service revenues.
|
Net
Sales
|
Percent
Increase
(Decrease)
Actual
Dollars
|
Percent
Increase
(Decrease)
Constant
Currency
|
||||||||||
Quarter
Ended June 30, 2007
|
||||||||||||
Contact
Lens
|
$ |
192.6
|
10 | % | 8 | % | ||||||
Lens
Care
|
116.0
|
12 | % | 10 | % | |||||||
Pharmaceuticals
|
202.9
|
25 | % | 21 | % | |||||||
Cataract/Vitreoretinal
|
105.8
|
9 | % | 5 | % | |||||||
Refractive
|
32.2
|
(2 | %) | (5 | %) | |||||||
Total
|
$ |
649.5
|
14 | % | 11 | % | ||||||
Quarter
Ended July 1, 2006
|
||||||||||||
Contact
Lens
|
$ |
175.4
|
(6 | %) | (5 | %) | ||||||
Lens
Care
|
104.0
|
(25 | %) | (25 | %) | |||||||
Pharmaceuticals
|
162.1
|
9 | % | 9 | % | |||||||
Cataract/Vitreoretinal
|
97.3
|
2 | % | 2 | % | |||||||
Refractive
|
32.7
|
(13 | %) | (14 | %) | |||||||
Total
|
$ |
571.5
|
(6 | %) | (6 | %) | ||||||
Six
Months Ended June 30, 2007
|
||||||||||||
Contact
Lens
|
$ |
378.3
|
8 | % | 6 | % | ||||||
Lens
Care
|
213.6
|
8 | % | 6 | % | |||||||
Pharmaceuticals
|
371.1
|
17 | % | 12 | % | |||||||
Cataract/Vitreoretinal
|
201.0
|
6 | % | 2 | % | |||||||
Refractive
|
64.4
|
- | % | (3 | %) | |||||||
Total
|
$ |
1,228.4
|
10 | % | 6 | % | ||||||
Six
Months Ended July 1, 2006 1
|
||||||||||||
Contact
Lens
|
$ |
349.1
|
(2 | %) | 1 | % | ||||||
Lens
Care
|
198.4
|
(26 | %) | (25 | %) | |||||||
Pharmaceuticals
|
316.6
|
13 | % | 16 | % | |||||||
Cataract/Vitreoretinal
|
188.9
|
2 | % | 4 | % | |||||||
Refractive
|
64.5
|
(10 | %) | (10 | %) | |||||||
Total
|
$ |
1,117.5
|
(4 | %) | (2 | %) |
1
|
2006
lens care amounts reflect the impact of the voluntary recall of
MoistureLoc discussed in Recent Developments above and
in Part I, Item 1. Financial Statements of this Quarterly Report
on Form 10-Q under Note 12 — Market Withdrawal of MoistureLoc Lens
Care Solution. Provisions for sales returns and consumer rebates
associated with the recall reduced year-to-date lens care net sales
by
$19.1.
|
·
|
Contact
lens sales growth was mainly due to higher sales of PureVision
silicone hydrogel contact lenses (which led to overall higher sales
of
toric and multifocal products) combined with increased sales of
our
SofLens lines in China where depressed levels of a year ago
had
resulted from negative collateral impacts from the MoistureLoc
recall.
|
·
|
Second-quarter
lens care sales increased 10 percent on a constant-currency basis,
with
gains for both the ReNu and Boston brands. Sales gains
in the first six months of 2007 mainly reflect the impact of $19
of
provisions associated with the MoistureLoc recall that reduced
prior-year figures. Excluding those provisions, lens care sales
declined 2
percent on a reported basis and 4 percent in constant currency
in the
first half of 2007, reflecting lost MoistureLoc sales and lower
market share for our lines of multipurpose solutions following
the
recall.
|
·
|
In
the pharmaceuticals category, sales growth was attributable to
our lines
of allergy, dry eye, anti-inflammatory, anti-infective and combination
products and ocular vitamins. Those gains outpaced declines in
revenues
from certain non-ophthalmic
medications.
|
·
|
Cataract/vitreoretinal
product category sales gains in the second quarter of 2007 were
mainly due
to higher sales of IOLs, which grew about 15 percent on a
constant-currency basis. IOL sales were up about 10 percent for
the first
six months of 2007, while sales of phacoemulsification products
declined,
as customers await the availability of our new Stellaris
platform.
|
·
|
For
both the quarter and year-to-date periods, constant-currency refractive
category sales trends reflected lower sales of per-procedure cards,
microkeratome blades, lasers and other equipment, and higher service
fee
revenues.
|
Second
Quarter Ended
|
Six
Months Ended
|
|||||||||||||||
June
30, 2007
|
July
1, 2006
|
June
30, 2007
|
July
1, 2006
|
|||||||||||||
Cost
of products sold
|
42.1 | % | 43.7 | % | 42.4 | % | 43.7 | % | ||||||||
Selling,
administrative and general
|
43.2 | % | 44.8 | % | 41.6 | % | 43.6 | % | ||||||||
Research
and development
|
8.5 | % | 8.7 | % | 8.6 | % | 8.4 | % |
Period
|
Total
Number
of
Shares
Purchased
1
|
Average
Price
Paid
Per
Share
|
Total
Number of
Shares
Purchased
as
Part of
Publicly
Announced
Programs
2,
3
|
Maximum
Number
of
Shares
that May
Yet
Be
Purchased
Under
the
Programs
2,
3
|
||||||||||||
April
1, 2007 – April 28, 2007
|
9,694
|
$ |
54.84
|
-
|
2,170,055
|
|||||||||||
April
29, 2007 – May 26, 2007
|
7,297
|
$ |
61.92
|
-
|
2,170,055
|
|||||||||||
May
27, 2007 – June 30, 2007
|
5,081
|
$ |
68.64
|
5,081
|
2,164,974
|
|||||||||||
Total
|
22,072
|
$ |
60.36
|
5,081
|
2,164,974
|
1
|
Shares
purchased during the second quarter ended June 30, 2007 include
purchases
pursuant to a publicly announced repurchase program (see footnote
2
below), share-based compensation plans and deferred compensation
plans.
|
2
|
On
January 27, 2004, the Board of Directors authorized a program to
repurchase up to two million shares of the Company's outstanding
Common
stock. There is no expiration date for this program. During the
second
quarter ended June 30, 2007, 5,081 shares were repurchased at an
average
price of $68.64. Shares repurchased after November 2005 were primarily
through private transactions with the rabbi trust for the Company's
Deferred Compensation Plan.
|
3
|
On
July 26, 2005, the Board of Directors approved the purchase of
up to an
additional two million shares of the Company's outstanding Common
stock.
There is no expiration date for this program, and since its approval
no
shares have been repurchased.
|
BAUSCH
& LOMB INCORPORATED
|
||
August 8, 2007 | /s/ Ronald L. Zarrella | |
Date
|
Ronald
L. Zarrella
Chairman
and
Chief
Executive Officer
|
|
August 8, 2007 | /s/ Efrain Rivera | |
Date
|
Efrain
Rivera
Senior
Vice President and
Chief
Financial Officer
|
S-K
Item
601
No.
|
Document
|
(3)-a
|
Restated
Certificate of Incorporation of Bausch & Lomb Incorporated (filed as
Exhibit (3)-a to the Company's Form 10-K for the fiscal year ended
December 31, 2005, File No. 1-4105, and incorporated herein by
reference).
|
(3)-b
|
Amended
and Restated By-Laws of Bausch & Lomb Incorporated, effective April
26, 2005 (filed as Exhibit (3)-e to the Company's Form 10-Q for
the
quarter ended June 25, 2005, File No. 1-4105, and incorporated
herein by
reference).
|
(4)-a
|
See
Exhibit (3)-a.
|
(4)-b
|
Form
of Indenture, dated as of September 1, 1991, between the Company
and
Citibank, N.A., as Trustee, with respect to the Company's Medium-Term
Notes (filed as Exhibit (4)-a to the Company's Registration Statement
on
Form S-3, File No. 33-42858 and incorporated herein by
reference).
|
(4)-c
|
Supplemental
Indenture No. 1, dated May 13, 1998, between the Company and Citibank,
N.A. (filed as Exhibit 3.1 to the Company's Current Report on Form
8-K,
dated July 24, 1998, File No. 1-4105 and incorporated herein by
reference).
|
(4)-d
|
Supplemental
Indenture No. 2, dated as of July 29, 1998, between the Company
and
Citibank, N.A. (filed as Exhibit 3.2 to the Company's Current Report
on
Form 8-K, dated July 24, 1998, File No. 1-4105 and incorporated
herein by
reference).
|
(4)-e
|
Supplemental
Indenture No. 3, dated November 21, 2002, between the Company and
Citibank, N.A. (filed as Exhibit 4.8 to the Company's Current Report
on
Form 8-K, dated November 18, 2002, File No. 1-4105 and incorporated
herein
by reference).
|
(4)-f
|
Supplemental
Indenture No. 4, dated August 1, 2003, between the Company and
Citibank,
N.A. (filed as Exhibit 4.1 to the Company's Current Report on Form
8-K,
dated August 6, 2003, File No. 1-4105 and incorporated herein by
reference).
|
(4)-g
|
Fifth
Supplemental Indenture, dated August 4, 2003, between the Company
and
Citibank, N.A. (filed as Exhibit 4.2 to the Company's Current Report
on
Form 8-K, filed August 6, 2003, File No. 1-4105, and incorporated
herein
by reference).
|
(4)-h
|
Sixth
Supplemental Indenture, dated December 20, 2004, between the Company
and
Citibank, N.A. (filed as Exhibit (4)-j to the Company's Annual
Report on
Form 10-K for the fiscal year ended December 25, 2004, File No.
1-4105 and
incorporated herein by reference).
|
(4)-i
|
Supplemental
Indenture No. 7, dated as of June 6, 2006 (filed as Exhibit (4)
to the
Company's Current Report on Form 8-K, filed June 12, 2006 and incorporated
herein by reference).
|
(4)-j
|
Supplemental
Indenture No. 8, dated as of November 8, 2006 (filed as Exhibit
(4)-j to
the Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2005, File No. 1-4105 and incorporated herein by
reference).
|
(4)-k
|
Amended
and Restated Supplemental Indenture No. 8, effective as of November
8,
2006 (filed as Exhibit (4)-k to the Company's Annual Report on
Form 10-K
for the fiscal year ended December 31, 2005, File No. 1-4105 and
incorporated herein by reference).
|
(4)-l
|
Supplemental
Indenture No. 9, effective as of January 31, 2007 (filed as Exhibit
(4)-k
to the Company's Annual Report on Form 10-K for the fiscal year
ended
December 30, 2006, File No. 1-4105 and incorporated herein by
reference).
|
(10)-a
|
Steven
C. McCluski Separation Letter, dated June 29, 2007 (filed
herewith).
|
(10)-b
|
Paul
G. Howes Separation Letter, effective April 9, 2007 (filed as Exhibit
(10)-rr to the Company's Annual Report on Form 10-K for the year
ended
December 26, 2006, File No. 1-4105 and incorporated herein by
reference).
|
(10)-c
|
Amendment
No. 1 to Credit Agreement, effective April 11, 2007 (filed as Exhibit
99.1
to the Company's Current Report on Form 8-K, filed April 13, 2007,
File
No. 1-4105 and incorporated herein by reference).
|
(10)-d
|
Amendment
to B.V. Term Loan Agreement, effective April 12, 2007 (filed as
Exhibit
99.2 to the Company's Current Report on Form 8-K, filed April 13,
2007,
File No. 1-4105 and incorporated herein by reference).
|
(10)-e
|
Agreement
and Plan of Merger among WP Prism LLC, WP Prism Merger Sub Inc.
and Bausch
& Lomb Incorporated, dated as of May 16, 2007 (filed as Exhibit 99.1
to the Company's Report on Form 8-K, filed May 16, 2007, File No.
1-4105
and incorporated herein by reference).
|
(10)-f
|
Letter
Waiver (U.S. Credit Agreement), dated May 25, 2007 (filed as Exhibit
99.1
to the Company's Current Report on Form 8-K filed May 29, 2007,
File No.
1-4105 and incorporated herein by reference).
|
(10)-g
|
Letter
Waiver (B.V. Term Loan), dated May 25, 2007 (filed as Exhibit 99.2
to the
Company's Current Report on Form 8-K filed May 29, 2007, File No.
1-4105
and incorporated herein by reference).
|
(31)-a
|
Certification
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed
herewith).
|
(31)-b
|
Certification
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed
herewith).
|
(32)-a
|
Certification
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C.
Section 1350 (furnished herewith).
|
(32)-b
|
Certification
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C.
Section 1350 (furnished herewith).
|